Chemical Name:Eliglustat
- CAS No.491833-29-5
- Molecular Formula:C23H36N2O4
- Formula Weight:404.55
Synonyms:Eliglustat;Genz 99067;N-[(1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]-octanamide;N-[(1R,2R)-1-(2
*The following content is generated by AI and is for reference only.
Eliglustat powder, identified by CAS number 491833-29-5, is a critical pharmaceutical intermediate and active pharmaceutical ingredient (API) primarily utilized in the treatment of Gaucher disease type 1. This compound functions as a specific substrate reduction therapy (SRT) agent. By selectively inhibiting glucosylceramide synthase, Eliglustat reduces the production of glucosylceramide, thereby preventing its accumulation in macrophages, which is the hallmark pathological feature of Gaucher disease. The product described as "99% up GMP" indicates a high-purity grade manufactured under Good Manufacturing Practice standards, ensuring it meets rigorous quality control requirements for clinical and commercial applications.
The molecular formula of Eliglustat tartrate is typically C27H46N2O2·C4H6O6 when considering the salt form, while the free base structure corresponds to C27H46N2O2. Its precise chemical identity allows for consistent pharmacological performance in therapeutic regimens. As a key component in the formulation of drugs like Cerdelga (eliglustat tartrate), this powder serves as the foundational building block for oral capsules designed to manage symptoms and improve quality of life for patients with lysosomal storage disorders.
In the global supply chain, high-quality Eliglustat powder sourced from GMP-compliant facilities is essential for pharmaceutical manufacturers aiming to produce reliable medications. The availability of this material at purity levels exceeding 99% ensures minimal impurities, which is vital for patient safety and regulatory approval. Researchers and biopharmaceutical companies frequently utilize this substance for further drug development, stability testing, and formulation studies. The demand for such specialized intermediates continues to grow as awareness of rare diseases increases and new treatment protocols are established. Ultimately, Eliglustat represents a significant advancement in targeted metabolic therapies, offering a non-enzyme replacement option that effectively manages the underlying cause of the disease rather than just alleviating symptoms.
(All Rights Reserved)
